Comparative Pharmacology
Head-to-head clinical analysis: DANAZOL versus DANZITEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANAZOL versus DANZITEN.
DANAZOL vs DANZITEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), preventing export of tumor suppressor proteins and growth regulators from the nucleus, leading to cell cycle arrest and apoptosis.
300-600 mg orally twice daily; maximum 800 mg/day
1.5 mg orally once daily, increased at 2-week intervals to 3 mg once daily, then 5 mg once daily based on tolerability and efficacy.
None Documented
None Documented
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Approximately 10-12 hours in adults; may be prolonged in hepatic impairment (up to 20 hours).
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Primarily hepatic metabolism followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Category C
Category C
Androgen/Antigonadotropin
Androgen/Antigonadotropin
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."